As shown in Figure 4, DN patients were on different management plans, including diet modifications, oral hypoglycaemic agents, oral hypoglycaemic agents and insulin, and insulin only in 27.5%, 35%, 25%, and 40% of them, respectively. This evidence concerns the gene INS and liver dysplastic nodule.